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Abstract.  In a  number of recent studies it has been 
shown that in vivo part of the EGF receptor (EGFR) 
population is associated to the actin filament system. 
In this paper we demonstrate that the purified EGFR 
can be cosedimented with purified filamentous actin 
(F-actin) indicating a direct association between EGFR 
and actin. A  truncated EGFR, previously shown not 
to be associated to the cytoskeleton, was used as a 
control and this receptor did not cosediment with ac- 
tin filaments. Determination of the actin-binding do- 
main of the EGFR was done by measuring competi- 
tion of either a  polyclonal antibody or synthetic 
peptides on EGFR cosedimentation with F-actin. A 
synthetic peptide was made homologous to amino 
acid residues 984-996  (HL-33) of the EGFR which 
shows high homology with the actin-binding domain 
of Acanthamoeba  profilin. A  polyclonal antibody 
raised against HL-33 was found to prevent cosedimen- 
tation of EGFR with F-actin. This peptide HL-33 was 
shown to bind directly to actin in contrast with a  syn- 
thetic peptide homologous to residues  1001-1013 
(HL-34).  During cosedimentation, HL-33 competed 
for actin binding of the EGFR and HL-34 did not, in- 
dicating that the EGFR contains one actin-binding 
site.  These results demonstrate that the EGFR is an 
actin-binding protein which binds to actin via a  do- 
main containing amino acids residues 984-996. 
T 
hE EGF receptor (EGFR) ~ is a transmembrane gly- 
coprotein of 170 kD with an extracellular EGF bind- 
ing domain, a single hydrophobic membrane spanning 
stretch,  and an intracellular tyrosine kinase domain (33). 
Binding of EGF to the receptor leads to dimerization of the 
receptor and subsequent activation of the tyrosine kinase 
(30, 31, 42), thereby catalyzing tyrosine phosphorylation of 
several protein substrates including the receptor itself (16). 
Activation of the receptor kinase results in a cascade of bio- 
chemical  and  physiological responses,  finally leading  to 
stimulation of DNA synthesis in most cells (7). The tyrosine 
kinase activity was demonstrated to be essential for stimula- 
tion of all known early and late responses involved in EGF- 
induced mitogenic signaling (14, 22, 26). 
EGF binding studies revealed the presence of at least two 
classes of EGFR differing in their affinity of EGF binding, 
(3, 4, 18), although no evidence is available for heterogeneity 
of the EGFR primary structure. The low affinity receptors 
are usually more abundant, but the high affinity class appears 
to be primarily responsible for induction of the cellular re- 
sponses to EGF, as deduced from studies in which antibodies 
were used that specifically inhibited binding of EGF to the 
low affinity but not to the high affinity receptors (11). Given 
this major role for the high-affinity class of receptors  in 
EGF-induced signal transduction, it is of particular interest 
to note that the high affinity receptors are associated to the 
cytoskeleton (21, 29, 35, 36, 37, 41). It is therefore tempting 
1. Abbreviations  used in this paper: EGFR, EGF receptor; Ptdlns, phospha- 
tidylinositol; Ptdlns(4)P, Ptdlns (4) phosphate. 
to suggest that the cytoskeleton has an important function in 
EGF-induced signal transduction. 
This suggestion is supported by the observation that EGFR 
tyrosine kinase activation leads to phosphorylation of several 
cytoskeleton-associated proteins, such as the actin-binding 
proteins annexin I, vinculin, and spectrin (1, 6, 12, 15). Fur- 
thermore, several components involved in the EGF-induced 
signal transduction, among them phospholipase C, phospha- 
tidylinositol (Ptdlns)  kinase,  phosphatidylinositol(4)phos- 
phate (Ptdlns(4)P) kinase, and diacylglycerol kinase, have 
been demonstrated to be associated to the cytoskeleton of 
A431  cells, in particular to the actin microfilament system 
(24).  Finally, using double-immunofluorescence labeling, it 
has been demonstrated that the EGFR colocalizes with actin 
filaments, both in control and EGF-stimulated cells (28, 38). 
Altogether these observations point to a close interaction be- 
tween the EGFR and the actin microfilament system. 
Support for this interaction was subsequently obtained by 
selective extraction of cytoskeletons of A431  cells. It was 
shown that 90% of the cytoskeleton-associated EGFR popu- 
lation was removed from the cytoskeleton together with the 
actin  filamentous system,  while during  several  cycles of 
poly-  and depolymerization of actin  isolated from A431 
cells, the EGFR sedimented together with polymerized actin 
(38). Furthermore, it was demonstrated that immunoprecipi- 
tation of  cytoskeleton-associated  EGFR resulted in a specific 
coprecipitation of actin,  while actin did not coprecipitate 
with nonionic detergent-solubilized EGFR (28).  However, 
so far it is not clear whether the interaction of  the EGFR with 
actin filaments is mediated by other actin-binding proteins, 
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tors (9, 45), or whether the EGFR binds directly to actin. 
We have addressed this question by studying the associa- 
tion of the purified EGFR with purified actin in vitro. We 
demonstrate that the EGFR specifically binds to polymer- 
ited actin with no other proteins involved. EGF receptors 
contain  one  actin-binding  site  which  is  located between 
amino acid residues 984-996 of the intracellular domain. 
Materials and Methods 
Cell Culture 
A431  e  pidermoid carcinoma cells were grown in DME (Gibco, Palsle); 
Scotland) supplemented with 7.5%  FCS (Integro, Zaandam, the Nether- 
lands) in 1,750 cm  2 roller bottles (Falcon, Becton Dickinson Labware, UK) 
to confluency. 
EGF Receptor Purification 
Cells were washed twice with PBS and detached with PBS containing 1 mM 
EDTA. The cells were collected by means of centrifugation for 10 rain at 
800 g, suspended in solubilization buffer containing 10 mM Tris-HC1  (pH 
7.4),  1% Triton X-100, 10% glycerol, 150 mM NaCI, 1 mM EDTA, 5 #g/ml 
leupeptin, 5 mM benzamidin,  1% aprotinin,  1 mM PMSF and incubated 
during 1 h on ice. The insoluble material was removed by centrifugation 
at 100,000  g  for 1 h at 0~  The clear supernatant was passed through a 
small column of Sepharose CL-4B (Pharmacia, Uppsala, Sweden) which 
contained covalently coupled 2E9, mAb directed against the external do- 
main of the EGFR (11). The column was successively washed with 100 mi 
of the following buffers: (a) 10 mM "IMs-HCI (pH 7.4),  0.1% Triton X-100, 
10% glycerol, 1 M NaC1,  1 mM EDTA, 5 mM Benzamidin, 1% aprotinin, 
1 mM PMSF; (b) 10 mM Tris-HCl pH (7.4),  10% glycerol, I mM EDTA, 
5 mM benzamidin, 1% aprotinin, 1 mM PMSF; (c) 10 mM Lysine-NaOH 
(pH 9.5), 0.1%  Triton X-100,  10%  gl)~cerol,  150 mM NaCI, 5 mM ben- 
zamidin; and (d) 10 mM Hepes (pH 5.0),  10% glycerol, 150 mM NaCI, 
1 mM EDTA, 5 mM benzamidin. The bound EGF receptor was eluted from 
the affinity column with pH 11.5 elution buffer (10 mM Lysin-NaOH [pH 
11.5], 0.05%  Triton X-100,  150 mM NaC1,  10% glycerol, 1 mM EDTA, 
5 mM benzamidin). The eluate was immediately neutralized by the addition 
of I M Hepes (pH 7.4) and the purified receptor was stored at -80~  The 
truncated receptor was from mouse NIH-3T3 fibroblasts transfected with 
EGF receptor eDNA of which the cytoplasmic domain was deleted (26), 
and was purified essentially as described above. 
Binding ofl2~I-Labeled EGF to the Purified Receptor 
The t251-EGF was prepared by the chloramine-T method (10), specific ac- 
tivity varying between 200,000  and 900,000  cpm/ng EGE  Equilibrium 
EGF binding was performed in a final volume of 200 #1, which contained 
10 ng of purified EGF receptor, 20 mM Hepes (pH Z4), 0.1%  BSA, and 
0.1% Triton X-100.  125I-EGF (0.5 ng/rnl) and unlabeled EGF were mixed 
to a final EGF concentration varying from 0.1 to 200 ng/ml and binding was 
allowed for 2 h at room temperature. Nonspecific binding of these samples 
was determined separately by addition of 1,000 times excess of unlabeled 
EGE Subsequently, the receptor complexes were precipitated by adding 0.5 
mi 0.1% 3,-globulin in 0.1 M phosphate buffer (pH 7.4) and 0.5 mi of 20.4% 
polyethylene glycol 6,000 at room temperature. The samples were mixed 
and centrifuged for 5 min at 14,000 g. The pellets were washed twice with 
8.5% polyethylene glycol in 0.1 M  phosphate buffer (pH 7.4).  The radio- 
activity retained in the tubes was measured in a gamma counter (Crystal 
5412  Multi Detector Ria system; United Technologies Packard, IL). The 
binding data were analyzed using the LIGAND program as described previ- 
ously (3). 
Protein Kinase Assay of the Purified EGFR 
Autophosphorylation reactions were carried out in a final volume of 50 ~1 
containing 20 mM Hepes (pH 7.4),  10 mM MgC12, 3 mM MnC12, and 1 
mM DTT.  The EGFR (50 ng) was first incubated in this buffer with 100 
ng/mi EGF for 20 min at 250C and the kinase reaction was subsequently 
started by the addition of 10 #M ()'-32P)ATP  (10 #Ci per assay) (Amer- 
sham International, Amersham, UK) and continued for 3 rain at 30"C. The 
reaction was stopped by the addition of  sample buffer (20 mM Tris-HC1 [pH 
6.8],  33%  glycerol, 300 mM DTT,  6.7%  SDS, and 0.01% bromophenol 
blue) and the samples were boiled for 3 min. The samples were analyzed 
on 10% SDS-PAGE and by autoradiography. The bands of the EGFR were 
excised from the gel and counted with a liquid scintillation counter. 
Substrate phosphorylation was measured under the same conditions as 
described above using 5 mM angiotensin II as a substrate. The reaction was 
continued for 3 min at 30~  and stopped by the addition of 5 #1 of 10 mg/mi 
BSA and 5/~1 of 50% 'I'CA. Proteins were precipitated by centrifugation and 
40  #1  of the  supernatant  was  spotted onto P81  phosphocellulose filter 
(Whatman International,  Maidstone, UK). The filters were washed four 
times with 7.5 mM phosphoric acid and counted in a liquid scintillation 
counter, and results are presented as the mean of three independent experi- 
ments. 
Actin Purification 
Actin was purified essentially as described before (13, 44)  with minor 
modifications. A431  cells were washed twice with PBS and detached with 
PBS containing 1 mM EDTA.  Ceils were collected and pelleted at 800 g 
for 5 rain and suspended in 2 vol of a buffer containing 20 mM Tris-maleate 
(pH 7.0),  1 mM EDTA, 0.5 mM ATE 10 mM DTT,  0.34 M sucrose. The 
ceils were lysed by Dounce homogenization on ice. The homogenate was 
clarified by centrifugation at 100,000 g for 1 h at 4~  The clear supernatant 
was warmed to room temperature, supplemented with 75 mM KC1 and 2 
mM MgCI2,  and the solution was stirred for 90 min which induced poly- 
merization of actin.  The  precipitate  was  collected by  centrifugation at 
14,000  g for 2 min and the pellet was suspended in ice-cold Tris-maleate 
(pH 7.0) containing 0.6 M KCI. After centrifugation for 3 h at 80,000 g the 
pellet was dissolved in buffer G containing 2 mM Tris-HC1  (pH 8.0),  0.2 
mM ATE 0.5  mM /3-mercaptoethanot, 0.2 mM CaClz, and  10%  form- 
amide. After dialysis against the same buffer the solution was centrifuged 
at 80,000  g for 3 h. The supernatant was mixed with DNAse I coupled to 
Sepharose CL-4B for 2 h at 4~  After centrifugation at 2,000 g for 5 rain 
the affinity matrix was intensively washed with buffer G, subsequently with 
buffer G  containing 0.2 M  NHaCI  and again with buffer G.  Elution was 
done with buffer G containing 40% formamide and the eluate was immedi- 
ately diluted with buffer G without formamide to prevent denaturation of 
actin.  The  actin-contalning fraction was  concentrated by ultrafiltration 
using a Centrifugal Ultra Free unit (Millipore Corp., Bedford, MA) and 
stored in buffer G at 4~ 
SDS-PAGE and Immunoblotting 
Protein determination was done using the BCA-reagent (Pierce Chemical 
Company, Rockford, IL) with BSA as standard. Proteins were solubilized 
in sample buffer (20 mM Tris-HC1  [pH 6,8], 33% glycerol, 300 mM DTT, 
6.7%  SDS, and 0.01% bromophenol blue), separated on 10%  SDS-PAGE 
either stained with Coomassie brilliant blue or blotted onto nitrocellulose 
(Schleicher and Schuell, Dassel, Germany) as described previously (39). 
The nitrocellulose was blocked with 0.3% milk powder (Nutricia, Zoeter- 
meer, the Netherlands) in PBS for 45 rain at room temperature. The filters 
were incubated with antibodies for 1 h diluted in 0.03 % milk powder in PBS 
at room temperature. After washing in the same buffer the filters were in- 
cubated with secondary antibodies conjugated with alkaline phosphatase. 
The antibody reaction was visualized in 100 mM Tris-HCl (pH 9.5),  100 
mM NaC1, 50 mM MgC12 containing 0.33 mg/mi nitrobluetetrazolium salt 
and 0.17 mg/ml 5-bromo-4-chloro-3-indolyl phosphate toluidinium (Sigma 
Chemical Co.). 
Electron Microscopy 
Actin (300 #g/ml) was allowed to polymerize in vitro by the addition of 
MgC12 (final concentration 2 raM) and KCI (final concentration 75 raM). 
After 20 min of  polymerization, grids covered with carbon-coated Forrnvar 
film were incubated for 30 s with the F-actin-containing solution. After a 
bri[f wash with polymerization buffer, the actin was negatively stained with 
1% uranyl acetate. The grids were examined in a Philips CMIO electron mi- 
croscope with an accelerating voltage of 100 kV. 
Actin Sedimentation Assay 
The binding of EGFR and synthetic peptides to F-actin was examined by 
the sedimentation assay. EGFR (2 #g), truncated EGFR (1 t~g), six different 
proteins and synthetic peptides were incubated with 10 #g actin for 10 min 
in 200 #l buffer containing 2 mM Tris-HCl (pH 7.4), 0.2 mM CaC12, 0.2 
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pared according to standard procedures and labeled with 125I  according  to 
the chloramine-T method (10) yielding a  specific activity of 150,000- 
200,000 cpm/#g peptide. For competition assays with the polyclonal  anti- 
EGFR antibody  281-7, 100 ng EGFR was preincubated for 3 h with the anti- 
body before  adding the actin (10 #g). For competition  assays with synthetic 
peptides, 100 ng EGFR was preincubated with 10 #g actin in the presence 
of 5 mg synthetic peptide. All competition  experiments were performed in 
200 #1 buffer  containing  2 mM Tris-HC1 (pH 7.4), 0.2 mM CaCI2, 0.2 mM 
DTT, and 0.5 mM ATP. In all cases polymerization  of  the actin was induced 
by adding 75 mM KCI and 2 mM MgCI2  and after 1 h at room temperature 
the samples were centrifuged for 1 h at 100,000 g. The supernatants were 
removed, concentrated  by ultrafiltration, and mixed  with sample  buffer. The 
pellets were immediately dissolved in sample buffer. Pellets and superna- 
tants were either analyzed  on 10% SDS-PAGE  and stained with Coomassie 
brilliant blue or radioactivity in the pellet fraction was measured using a 
gamma counter. Nonspecific binding was determined in the presence of 
".,1,000-fold excess of unlabeled peptide and the results of two independent 
experiments are presented. 
Results 
EGFR and Actin Purification 
The investigation of the direct interaction between the EGFR 
and actin in vitro, requires the purification of both proteins 
to homogeneity. The EGFR was purified from A431 epider- 
moid carcinoma cells,  a  well-known rich source of EGFR 
since this cell line has been reported to contain '~2  ￿  106 
cell surface located receptors/cell, while these receptors rep- 
resent *20% of the total receptor population (8,  19). After 
cell extraction,  the EGFR was isolated by affinity chroma- 
tography using the monoclonal anti-EGFR antibody 2E9 as 
a  substrate.  This antibody recognizes an extracellular  pep- 
tide  determinant  of the  EGFR  (11).  After  elution  of the 
affinity  chromatography columns,  the  fractions  were  sub- 
jected to SDS-PAGE as described in Materials and Methods. 
As shown in Fig.  1 A, Coomassie brilliant blue staining of 
the purified fractions on gel revealed only one single protein 
band with an apparent molecular mass of 170 kD. Analysis 
of ~25I-EGF binding  to this  purified  protein,  according to 
the Scatchard method, revealed one single class of binding 
sites exhibiting an apparent dissociation constant KD of 8.0 
nM  (Fig.  1 B). 
To determine the kinase activity of the purified receptor, 
EGF (100 ng/ml) was added to the protein suspension in the 
presence of ~,-32p-ATP as described in Materials  and Meth- 
ods.  SDS-PAGE,  autoradiography,  and  subsequent  quanti- 
fication  of incorporated  radioactivity  in  the  protein  band 
revealed that EGF caused a twofold increase in receptor au- 
tophosphorylation,  yielding a  ratio of 32p/receptor of ~1.5 
(Fig. 1 C). In addition, the purified protein was able to phos- 
phorylate exogenous substrates  in the presence of EGF,  as 
shown in Fig. 1 D for angiotensin II. In this particular experi- 
ment  EGF  caused a  fourfold stimulation  of angiotensin  II 
phosphorylation  within  3  min.  These  results  demonstrate 
that the EGFR is purified to homogeneity, and exhibits EGF- 
binding capacity and EGF-induced tyrosine kinase activity. 
Actin was also purified  from A431  cells using a  DNAse 
I  affinity  column as  described  in  Materials  and  Methods. 
DNAse I has been shown to bind actin with a  high affinity 
and specificity (44).  After elution,  SDS-PAGE and staining 
of the purified fractions by Coomassie brilliant blue, one sin- 
gle band was detected with an apparent molecular mass of 
43 kD (Fig.  2 A). This purified protein is recognized by an 
antiactin antibody as shown by immunoblotting in Fig. 2 B. 
Under the conditions employed, actin is purified in its mono- 
meric form, but is able to polymerize in vitro by the addition 
of MgCI2 and KC1,  as  described  by Zechel  (44).  The pu- 
rified actin was incubated at room temperature  for 20 min 
Figure 1. Purification and characterization of the EGFR. (A) The EGFR was purified from Triton X-100 extracts of A431 cells as described 
in Materials and Methods.  The samples  were analyzed on 10% SDS-PAGE and stained  with Coomassie brilliant  blue.  (Lane 1) Triton 
X-100 extract of A431 cells; (lane 2) purified EGFR. (B) Scatchard  analysis  of EGF binding to the purified  EGFR. The receptor was 
incubated with different concentrations of EGF (0.1-200  ng/ml) for 2 h at room temperature and free EGF was removed by centrifugation 
for 5 min at 14,000 g. Binding data were analyzed using the LIGAND program. (C) Antophosphorylation of the purified  receptor in the 
absence (-EGF) and presence (+EGF) of EGE The receptor was preincubated with EGF for 20 min at 25~  and the kinase reactions 
were started by the addition of 3,-32p-ATP and continued for 3 min at 30~  The reactions were stopped by the addition of sample buffer 
and the samples were boiled for 3 min. The samples  were analyzed on 10%  SDS-PAGE followed by autoradiography.  (D) Angiotensin 
II phosphorylation by the purified EGFR in the absence (-EGF) and presence (+EGF) of EGE Reactions were carried out as described 
above in the presence of 5 mM Angiotensin H and 50 ng purified  EGFR. The reactions were stopped by the addition of 5 #1 BSA (10 
mg/ml) and 5 #1 of 50% TCA. After centrifugation, 40 tzl of the supernatant was spotted onto a PS1 phosphocellulose filter washed four 
times with phosphoric acid and counted in a liquid  scintillation  counter. 
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purified from A431 cells as described  in Materials  and Methods, 
analyzed on 10% SDS-PAGE, and stained with Coomassie brilliant 
blue.  (Lane  1)  Supernatant  of A431 cell  lysates  after Dounce 
homogenization  and centrifugation;  (lane 2)  purified  actin  after 
DNAse I affinity chromatography. (B) Immunoblot analysis of the 
purified actin. A431 cell lysates and purified actin were separated 
on 10% SDS-PAGE, blotted onto nitrocellulose, and analyzed for 
the presence of actin using a monoclonal antiactin (Amersham In- 
ternational, Amersham, UK). (Lane 1) A431 cell lysates; (lane 2) 
purified actin. (C) Electron micrograph of the purified actin. Actin 
was allowed to polymerize  in vitro by the addition of MgCI2 and 
KCI. Samples of the polymerized actin were attached to grids cov- 
ered with carbon-coated formvar film, and negatively stained with 
1% uranyl acetate. Bar, 0.1  #m. 
in the presence of 10 mM MgC12 and 75 mM KC1. A  sam- 
ple of the F-actin containing solution was prepared for elec- 
tron  microscopical examination as  described  in  Materials 
and Methods.  As shown in Fig. 2  C, the purified protein is 
able  to polymerize to  filamentous  structures  having a  di- 
ameter of ~4 nm, which is in agreement with the diameter 
of actin microfilaments (25). 
Association of the EGFR with Actin In Vitro 
Aliquots  of purified  EGFR and  of purified actin were in- 
cubated at room temperature in the presence of MgC12 and 
KC1 for 60  min  as  indicated.  Subsequently  the  actin fila- 
ments were sedimented by centrifugation at 100,000 g for 1 h 
at room temperature.  The  supernatant  containing  unpoly- 
merized actin was removed and concentrated by ultrafiltra- 
tion. Samples of both pellet and supernatant were separated 
on SDS-PAGE and analyzed after Coomassie brilliant blue 
staining. In the absence of actin, the EGFR was detected in 
the  supernatant  while  no EGFR was present in  the  pellet 
fractions (Fig. 3, lanes 1P and S). However, in the presence 
of actin and after actin polymerization, the EGFR was found 
to be present in the pellet and not in the supernatant (Fig. 
3, lanes 2P and S). These results demonstrate that all EGFRs 
bind to  F-actin,  but not to G-actin,  since the  supernatant 
fraction (Fig.  3,  lane 2S) did contain actin but no EGFR. 
To  determine  the  specificity  of  the  association  of  the 
EGFR to F-actin, a number of control experiments were per- 
formed. A truncated EGFR was purified from NIH-3T3 cells 
expressing an EGFR that lacks almost the entire cytoplasmic 
domain.  Previously we have shown that the EGFR of this 
mutant is not associated with the cytoskeleton in vivo (35). 
Figure 3. Actin sedimentation in the presence of EGFRs and control 
proteins. The EGFR, the truncated EGFR, G-actin, and six differ- 
ent control proteins were incubated as indicated.  G-actin was al- 
lowed to polymerize  for 1 h at room temperature, and after centrifu- 
gation the pellets (P) and supernatants (S) were analyzed on 10% 
SDS-PAGE and stained with Coomassie brilliant  blue.  (Lanes 1) 
EGFR (2/~g); (Lanes 2) EGFR (2 ttg) and G-actin (10/~g); (Lanes 
3) truncated EGFR (1/~g) and G-actin (10 ~tg); (Lanes 4) control 
proteins and G-actin (10/zg). 
Incubation of the purified truncated EGFR in the presence 
of actin and subsequent actin polymerization,  followed by 
analysis on SDS-PAGE as described above, reveals that the 
truncated receptor remains in the supernatant and not in the 
pellet (Fig. 3, lanes 3P and S), in contrast to the wild type 
EGFR (Fig. 3, lanes 2P and S). Furthermore, in order to ex- 
clude a  possible nonspecific association of the receptor to 
F-actin by trapping of the receptor in the actin filament net- 
work, the same experiment was performed using a mixture 
of proteins with molecular masses of 200,  116, 98,  68,  45, 
and 29 kD, respectively. As shown in Fig.  3 (lanes 4P and 
S), none of these proteins were found in the pellet, but in- 
stead they were present in the supernatant. 
These results clearly demonstrate that the association of 
the EGFR to F-actin is highly specific and requires the cyto- 
plasmic domain of the receptor.  Furthermore,  it is  shown 
that in vitro the EGFR binds directly to F-actin with no other 
proteins involved, demonstrating that the EGFR is an actin- 
binding protein. 
Effect of  Antibody 281-7 on EGFR Binding to F-Actin 
Of particular interest appears the observation that the amino 
acid  sequence of the  EGFR domain involving amino acid 
residues 986-999  appears to have high homology with the 
actin-binding domain of profilin of Acanthamoeba  (39) (Fig. 
4). To obtain evidence on the involvement of this domain of 
the EGFR in the binding to actin, we have determined the 
effect of the polyclonal anti  EGFR antibody 281-7  on the 
cosedimentation of the EGFR with actin. This antibody was 
raised against a  synthetic peptide corresponding to amino 
acid residues 984-996  (HL-33) of the EGFR (11) (Fig. 4). 
A  preincubation of the antibody 281-7  and the EGFR,  fol- 
lowed by incubation with actin,  subsequent actin polymer- 
ization, and detection on SDS-PAGE of  both supernatant and 
pellet fractions revealed that preincubation of the antibody 
and EGFR prevented the interaction of the EGFR with actin. 
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Figure 4.  Characterization  of synthetic  peptides.  (A)  Schematic 
representation  of the EGFR. Indicated are the EGF-binding site, 
the transmembrane  region,  the tyrosine kinase domain (Y-kinase) 
and the autophosphorylation  sites (Y). Synthetic peptides  HL-33 
and HL-34 are homologous with the indicated regions of the cyto- 
plasmic domain of the receptor. (B) Sequence comparison of HL-33 
and HL-34 with Acanthamoeba  profilin. Residues of HL-33 that are 
homologous with profilin are indicated and this sequence has been 
suggested as being the actin-binding site (33). 
Under these conditions the EGFR and antibody 281-7 were 
found to be present in the supernatant and not in the pellet 
fractions (Fig. 5, lanes P and S), which is clearly in contrast 
to EGFR incubated in the absence of antibody 281-7  (Fig. 
3, lanes 2P and S).  These results indicate that the antibody 
and F-actin compete for binding to the EGFR. This competi- 
tion may be due to steric hindrance,  in that the antibody is 
masking the actin-binding site of the EGFR. Alternatively, 
the competition may be caused by the fact that antibody 281-7 
and F-actin bind to the same domain of the EGFR. 
ldenttfication of the Actin-binding Domain 
of the EGFR 
To determine whether the amino acid residues 984-996 rep- 
resent the actin-binding domain of the EGFR, synthetic pep- 
Figure 5.  Effect of antibody 
281-7 on EGFR cosedimenta- 
tion  with  actin.  EGFR  (100 
ng)  was  preincubated  in  the 
presence  of anti-EGFR anti- 
body  281-7 as  described  in 
Materials and Methods. After 
adding 10/~g actin,  polymer- 
ization of actin was performed 
for 1 h at room temperature. 
After sedimentation the pellet 
(P) and supernatant  (S) were 
analyzed on 10% SDS-PAGE 
and  stained  with  Coomassie 
brilliant blue. 
Figure 6.  Analysis with  syn- 
thetic  peptides  HL-33  and 
HL-34. (A) Binding of HL-33 
and  HL-34  to  actin.  Syn- 
thetic  peptides  were  labeled 
with  125I. Actin  (30 /~g) was 
incubated with HL-33  (1  /~g) 
and HL-34 (1/~g). After poly- 
merization, actin was precipi- 
tated by centrifugation for 1 h 
at  100,000 g.  Binding of the 
synthetic peptides to the actin 
pellet  (HL-33, HL-34) was 
measured in a gamma counter. 
Nonspecific binding  was de- 
termined  by  1,000 times  ex- 
cess nonlabeled peptide (HL- 
33 AS, HL-34 AS). (B) Effect 
of synthetic  peptides  HL-34 
and HL-33 on EGFR cosedi- 
mentation  with  actin.  Actin 
(10 #g) was incubated with the 
EGFR  (100 ng)  in the  pres- 
ence  of 5  mg synthetic  pep- 
tides HL-34 and HL-33. Actin 
was allowed to polymerize for 1 h at room temperature. After sedi- 
mentation the pellets (P) and supernatants  (S) were analyzed on 
10% SDS-PAGE and stained  with Coomassie brilliant blue. 
tide HL-33 was analyzed for actin-binding capacity using the 
sedimentation assay. As a control, a synthetic peptide homol- 
ogous to residues 1001-1013 (HL-34) was used (Fig. 4). Both 
peptides, HL-33 and HL-34, were iodinated as described in 
Materials  and  Methods  and  the  ~25I-labeled peptides  were 
incubated in the presence of actin. After actin polymeriza- 
tion, the F-actin was separated from the unpolymerized actin 
by centrifugation,  and the radioactivity was determined in 
pellet and supernatant fractions. As shown in Fig. 6 A, HL- 
33  binds  to  F-actin  in  contrast  to  peptide  HL-34.  The 
specificity of peptide binding  was analyzed by measuring 
peptide binding in the presence of excess unlabeled peptide 
(Fig. 6 A). These results demonstrate unequivocally that the 
cytoplasmic domain  of the  EGFR  containing  amino  acid 
residues 984-996 is able to bind directly to F-actin, with no 
other proteins involved. 
An important question  is whether the residues 984-996 
represent the only actin-binding site of the EGF receptor. To 
test this, the sedimentation assay was performed in the pres- 
ence of either HL-33 or HL-34. As shown in Fig. 6 B, HL-33 
competes for actin binding of the EGFR while HL-34 does 
not, demonstrating that residues 984-996 of the cytoplasmic 
domain of the EGFR represents the only actin-binding site 
of the EGFR. 
Discussion 
A  number of recent studies have shown that growth factor 
receptors may be associated in vivo, to the cytoskeleton, in- 
cluding receptors for nerve growth factor (34), PDGF (45), 
and EGF (41).  Especially the interaction of the EGFR with 
the cytoskeleton has gained considerable interest, since bind- 
ing  studies  demonstrated  that  the  cytoskeleton-associated 
EGFR was of the high affinity class (37, 41), and this high- 
den Hartigh et al. EGF Receptors Bind to F-Actin  353 affinity class was shown to be responsible for EGF-induced 
signal transduction (2, 11). An interesting aspect of the inter- 
action between the EGFR and the cytoskeleton involves the 
nature of the cytoskeletal component. As judged by the di- 
ameter of the elements as observed in the electron micro- 
scope,  it has  been suggested that actin  is  involved in  the 
association  (41).  This  suggestion was  supported by a  co- 
localization of EGFR and actin filaments using immunofluo- 
rescence microscopy (5, 28, 38). Furthermore, it was shown 
that  immunoprecipitation  of  the  cytoskeleton-associated 
EGFR resulted in a coprecipitation of actin (28), while se- 
lective extraction of cytoskeletons revealed also an interac- 
tion between EGFR and actin filaments (38). 
Although these results clearly demonstrate that the EGFR 
is bound to actin, it is not known whether the EGFR is bound 
directly to actin or whether other proteins are involved in this 
association. Therefore, we have studied in this paper the in- 
teraction of EGFR and actin in vitro using highly purified 
components. EGFR and actin were purified and they were 
shown to be biologically active. The isolated EGFR binds 
EGF with a KD of 8.0 nM and EGF binding stimulates tyro- 
sine kinase activity and actin is shown to polymerize in vitro 
into 4-nm filaments. Using the cosedimentation assay,  it is 
demonstrated that all EGFRs are able to bind directly to ac- 
tin via its cytoplasmic domain with no other proteins in- 
volved. The actin-binding domain of the EGFR is present in 
residues 984-996 and appears to be the only actin-binding 
site of the EGFR. These findings are supported by the ho- 
mology of the EGF receptor domain containing amino acid 
residues  989-994  with  that  of the  actin  binding  site  of 
profilin of Acanthamoeba  (35). 
As shown in this paper, all EGFRs are able to bind to actin 
in vitro which is in agreement with the fact that no heteroge- 
neity exists in the EGF-receptor primary structure (33). In 
vivo, however, only 5 % of the receptor population appears 
to be associated to the cytoskeleton (37, 41) which suggest 
that in vivo the binding of EGFR to actin filaments is subject 
to stringent regulation. An explanation for this observation 
is a  possible competition for the actin-binding  site of the 
EGFR between actin and other proteins. Alternatively, regu- 
lation of actin polymerization may be involved in modulating 
EGFR association to the cytoskeleton. EGF is stimulating 
actin polymerization in the cortical skeleton while at the 
same time an increased number of cytoskeleton-associated 
EGFRs is observed (28,  37). A possible regulatory way for 
actin polymerization involves the action of profilin, a well 
known actin-binding protein. The activity of profilin is al- 
tered upon association with PtdlnsP2  (25,  43).  Binding of 
profilin to PtdlnsP2 results in dissociation of profilin-actin 
complexes, resulting in actin polymerization (20). Further- 
more, activation of the EGFR tyrosine kinase by binding of 
EGF results in activation of several kinases involved in the 
conversion of Ptdlns  to PtdlnsP2  (23,  40).  The increased 
level  of PtdlnsP2  may  result  in  an  increased  binding  of 
profilin and subsequent actin polymerization. Furthermore, 
the increased F-actin content may then in its turn bind to the 
EGFR,  thereby explaining the observed EGF-induced as- 
sociation of EGFR to the cytoskeleton (37). In addition, the 
regulation  of actin  polymerization may  be  influenced by 
other  actin-binding  proteins  which  may  be  regulated  by 
EGF-induced activation of the receptor kinase. 
An intriguing aspect concerns the biological function of 
the  interaction  of  EGFR  with  actin.  The  cytoskeleton- 
associated  EGFRs  appear  to  be  high  affinity  receptors, 
which suggests that the cytoskeleton is involved in the deter- 
mination of receptor affinity (5). However, EGF induces the 
association of low affinity receptors to the cytoskeleton, in- 
dicating that the cytoskeleton alone is unlikely to represent 
the primary determinant of receptor affinity (37). Alterna- 
tively, it has recently been demonstrated that a number of 
proteins involved in EGF-induced signal transduction, such 
as Ptdlns-4 kinase,  Ptdlns(4)P-5 kinase,  diacylglycerol ki- 
nase, and phospholipase C, are also associated to the actin 
microfilament system (24). These findings suggest that the 
actin microfilaments may act as a matrix in the formation of 
protein complexes consisting  of the  receptor and  its  sub- 
strates.  This matrix  may increase the  efficiency of signal 
transduction between the receptor and its substrates. Support 
for this hypothesis has been obtained by Rebillard and co- 
workers who showed that the actin microfilament system is 
involved in regulation of oncogene expression (27). Further- 
more, translocation of activated protein kinase C was found 
to depend upon actin filaments (17). These findings suggest 
that the actin microfilaments are involved in gene regulation 
either by interacting directly with  the  signal  transduction 
cascade,  or by compartmentalization of regulatory mole- 
cules in responses to signals arriving at the cell surface. By 
regulating the actin microfilament system, EGF may regulate 
the cellular system for optimal signal transduction. 
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